

# Modèles non linéaires à effets mixtes, pénalités structurées et algorithme SAEM

E Ollier<sup>1</sup>, A Samson<sup>2</sup>, X Delavenne<sup>1</sup>, V Viallon<sup>3</sup>

(1) Groupe de Recherche sur la Thrombose, EA3065, Université Jean Monnet,  
Saint-Etienne, France

(2) Université Grenoble-Alpes, Laboratoire Jean Kuntzmann, UMR CNRS 5224,  
Grenoble, France

(3) Université de Lyon, F-69622, Lyon, France

# Group Comparison with Non Linear Mixed Effect Model (NLMEM)

Non Linear mixed effects model (NLMEM) for groups of subjects ( $g = 1, \dots, G$ ) :

$$y_{i,j}^g = f(t_{i,j}^g, \phi_i^g) + h(t_{i,j}^g, \phi_i^g) \epsilon_{i,j}^g \text{ with } \epsilon_{i,j}^g \sim \mathcal{N}(0, 1)$$

$$\phi_i^g = A_i^g \begin{pmatrix} \mu^g \\ \beta^g \end{pmatrix} + \omega_i^g \text{ with } \omega_i^g \sim \mathcal{N}(0, \Omega^g)$$

$\Omega^g$  diagonal

$$h = af + b$$


## Hypothesis

$\mu^{g1} - \mu^{g2}$ ,  $\Omega^{g1} - \Omega^{g2}$ ,  $\beta^{g1} - \beta^{g2}$  and  $\beta$  are sparse

## Goal

Detect significant difference between group parameters

# Dabigatran PK with or without Clarithromycin<sup>1</sup>



Is there a drug-drug interaction ?

Parameters influenced by clarithromycin ?

<sup>1</sup>Delavenne et al., 2013

- **Stepwise methods:**

- Forward, Backward,...
- Based on Likelihood Ratio Tests (LRT) or BIC

- **Greedy approach:**

- All the possible model are evaluated  
↔ Difficult with large number of parameter

- **Penalized likelihood:**

- Preselect relevant models
- example: the LASSO <sup>2</sup> (covariates selection)

<sup>2</sup>Bertrand J, Balding DJ, 2013

# Joint Modelling with the Fused LASSO Penalty

When  $G = 2$ :

$$\text{ArgMin}_{\theta^1, \theta^2} \sum_{g=1}^2 -2LL(y^g, \theta^g) + \lambda \|\theta^1 - \theta^2\|_1$$

Estimate a vector  $\theta^1 - \theta^2$  that is sparse

$\lambda$  tunes the level of sparsity :

- $\lambda = 0 \Rightarrow$  between group differences are estimated for each parameters
- high levels of  $\lambda$  values  $\Rightarrow \theta^1 = \theta^2$


# Joint Modelling with the Fused LASSO Penalty

When  $G > 2$ :


$$\text{ArgMin}_{\theta^1, \dots, \theta^G} \sum_{g=1}^G -2LL(y^g, \theta^g) + \lambda \sum_{(g_1, g_2) \in \mathcal{E}} \|\theta^{g_1} - \theta^{g_2}\|_1$$

where  $\mathcal{E}$  is the edges set of a graph.

Clique Graph



Star Graph



# Penalty used in this work

- Fixed effects

$$P_F(\mu^1, \dots, \mu^G) = \sum_{(g_1, g_2) \in \mathcal{E}} \|\mu^{g_1} - \mu^{g_2}\|_1$$

- Random effects variances

$$P_V(\Omega^{1^{-1}}, \dots, \Omega^{G^{-1}}) = \sum_{(g_1, g_2) \in \mathcal{E}} \|\Omega^{g_1^{-1}} - \Omega^{g_2^{-1}}\|_1$$

- Covariates effects

$$P_C(\beta^1, \dots, \beta^G) = \sum_{(g_1, g_2) \in \mathcal{E}} \|\beta^{g_1} - \beta^{g_2}\|_1 + \sum_{g=1}^G \|\beta^g\|_1$$

## Some notations

- $\theta = (\theta^1, \dots, \theta^G)$
- $\theta^g = (\mu^g, \beta^g, \Omega^g, a, b)$
- $\mu = (\mu^1, \dots, \mu^G)$
- $\beta = (\beta^1, \dots, \beta^G)$



# SAEM algorithm for joint modeling ( iteration $k$ )

## ■ E step:

### 1 Simulation:

- simulation of  $\phi^g$  under  $p(\phi|y^g; \theta_k^g)$  by MCMC

### 2 Stochastic Approximation: Stochastic approximation of $\mathbb{E}[\log p(y^g, \phi^g, \theta^g) | y^g, \theta_k^g]$ :

- $Q_{k+1}^g(\theta) = \gamma_k \log p(y^g, \phi^g, \theta_k^g) + (1 - \gamma_k) Q_k(\theta)^1$

with  $(\gamma_k)$  sequence of decreasing step sizes

## ■ M step: actualization of $\theta$ :

$$(\theta_{k+1}^1, \dots, \theta_{k+1}^G) = \underset{\theta^1, \dots, \theta^G}{\text{ArgMax}} \sum_{g=1}^G Q_{k+1}^g(\theta^g)$$

# Introducing a penalty within SAEM

Classical SAEM algorithm (M-step):

$$(\theta_{k+1}^1, \dots, \theta_{k+1}^G) = \underset{\theta^1, \dots, \theta^G}{\text{ArgMax}} \sum_{g=1}^G Q_{k+1}^g(\theta^g)$$

Penalized SAEM algorithm (M-step):

$$(\theta_{k+1}^1, \dots, \theta_{k+1}^G) = \underset{\theta^1, \dots, \theta^G}{\text{ArgMax}} \sum_{g=1}^G Q_{k+1}^g(\theta^g) - P(\theta^1, \dots, \theta^G)$$

# Penalized version of SAEM algorithm ( iteration $k$ )

- E step:

UNCHANGED

- M step: actualization of  $\theta_k^g$ :

$$(\theta_{k+1}^1, \dots, \theta_{k+1}^G) = \underset{\theta^1, \dots, \theta^G}{\text{ArgMax}} \begin{cases} \sum_{g=1}^G Q_{k+1}^g(\theta^g) \\ -\lambda_F P_F(\mu^1, \dots, \mu^G) \\ -\lambda_C P_C(\beta^1, \dots, \beta^G) \\ -\lambda_V P_V(\Omega^{1-1}, \dots, \Omega^{G-1}) \end{cases}$$

# M step in details

1 Fixed effects update<sup>3</sup>:

$$(\mu_{k+1}, \beta_{k+1}) = \underset{\mu, \beta}{\text{ArgMax}} \begin{cases} \sum_{g=1}^G Q_k^g(\mu^g, \Omega_k^g, a_k, b_k) \\ -\lambda_F P_F(\mu^1, \dots, \mu^G) \\ -\lambda_C P_C(\beta^1, \dots, \beta^G) \end{cases}$$

2 Random effects variance update<sup>4</sup>:

$$(\Omega_{k+1}^1, \dots, \Omega_{k+1}^G) = \underset{\Omega}{\text{ArgMax}} \begin{cases} \sum_{g=1}^G Q_k^g(\mu_{k+1}^g, \Omega^g, a_k, b_k) \\ -\lambda_V P_V(\Omega^{1-1}, \dots, \Omega^{G-1}) \end{cases}$$

3 Error model's parameters update: same as in SAEM because they are not penalized.

<sup>3</sup>Boyd et al., 2011

<sup>4</sup>Danaher et al., 2011

# BIC Selection of Optimal $\lambda_F$ and $\lambda_V$ Values

- 1 Preselect relevant models by solving the fused LASSO problem on a grid of  $\lambda_F$  and  $\lambda_V$  values:

$$\left( (\lambda_F^m, \lambda_V^m) \in \mathbb{R}^2, m \in \{1, \dots, M\} \right)$$

- 2 The optimal model (among the preselected) is the one that minimize the BIC <sup>5</sup>:

$$BIC(\lambda_F, \lambda_V) = \sum_{g=1}^G -2LL(y^g, \tilde{\theta}_{\lambda_F, \lambda_V}^g) + \log(N) \times df_{\lambda_F, \lambda_V}$$

- $N$ : total number of patients
- $\tilde{\theta}_{\lambda_F, \lambda_V}^g$  : unpenalized reestimation of the selected model
- $df_{\lambda}$ : number of distinct coefficients (degree of freedom)

<sup>5</sup>Delattre et al., 2014

## Exemple: a Simulated Data Set with 3 Groups

- 100 patients per group
- Model : first order absorption, one compartment

$$C(t) = \frac{D}{V} \frac{k_a}{k_a - Cl} (e^{-\frac{Cl}{V}t} - e^{-k_a t})$$

- Fixed effects parameters were set to :


$$\begin{array}{lll} \mu_{Cl}^1 = 0.0597 & \mu_V^1 = 0.4819 & \mu_{k_a}^1 = 1.47 \\ \mu_{Cl}^2 = 0.0597 & \mu_V^2 = 0.4819 & \mu_{k_a}^2 = 2.18 \\ \mu_{Cl}^3 = 0.0420 & \mu_V^3 = 0.5784 & \mu_{k_a}^3 = 1.47 \end{array}$$

- Random effects variances were set to :


$$\begin{array}{lll} \Omega_{Cl}^1 = 0.1 & \Omega_V^1 = 0.1 & \Omega_{k_a}^1 = 0.1 \\ \Omega_{Cl}^2 = 0.1 & \Omega_V^2 = 0.1 & \Omega_{k_a}^2 = 0.25 \\ \Omega_{Cl}^3 = 0.2 & \Omega_V^3 = 0.1 & \Omega_{k_a}^3 = 0.2 \end{array}$$

- Penalty structure: clique graph

# SAEM Estimates



# Regularization path





# Model Selection Performance: Simulation Set up

- Model : first order absorption, one compartment
- 2 groups with 25, 50 or 100 patients per group
- Fixed effects parameters were set to :

$$\begin{aligned}\mu_{Cl}^1 &= 0.0597 & \mu_V^1 &= 0.4819 & \mu_{k_a}^1 &= 1.47 \\ \mu_{Cl}^2 &= 0.0420 & \mu_V^2 &= 0.5784 & \mu_{k_a}^2 &= 1.47\end{aligned}$$

- Random effects variances were set to :

$$\begin{aligned}\Omega_{Cl}^1 &= 0.1 & \Omega_V^1 &= 0.1 & \Omega_{k_a}^1 &= 0.1 \\ \Omega_{Cl}^2 &= 0.21 & \Omega_V^2 &= 0.1 & \Omega_{k_a}^2 &= 0.21\end{aligned}$$

- 50 simulations for each group size

# Model Selection Performance

	Fixed effects		
	25	50	100
Forward + BIC	30%	76%	68%
Fused + BIC	44%	74%	76%

	Variances		
	25	50	100
Forward + BIC	10%	30%	52%
Fused + BIC	38%	58%	78%

	Both		
	25	50	100
Forward + BIC	6%	24%	46%
Fused + BIC	14%	40%	60%

**Table:** Proportion of correctly selected model on 50 simulations for the fixed effects model, the variances model and the whole model

**Inverse Gaussian absorption model:**

$$IG(t) = Dose \times F \times \sqrt{\frac{MAT}{2\pi CV^2 t^3}} \times e^{\frac{-(t-MAT)^2}{2CV^2 MAT t}}$$
$$\frac{dD_c}{dt} = IG(t) - D_c \left( \frac{Q}{V_c} + \frac{Cl}{V_c} \right) + \frac{Q}{V_p} D_p$$
$$\frac{dD_p}{dt} = \frac{Q}{V_c} D_c - \frac{Q}{V_p} D_p$$

- Individual parameters: Log-Normal distribution
- Random effects on all the parameters

# Dabigatran PK with or without Clarithromycin

## First step:

- No covariates
- Effect of clarithromycin tested on 8 parameters:

- Absorption:

$$\mu_F, \mu_{MAT}, \mu_{CV} \text{ and } \Omega_F, \Omega_{MAT}, \Omega_{CV}$$


- Elimination:

$$\mu_{CI} \text{ and } \Omega_{CI}$$


## Second step:

- 8 SNP of the P-gp included as covariates on  $F$
- The model selected in first step was used for fixed and variance parameters

# Dabigatran PK with or without Clarithromycin: Results



# Dabigatran PK with or without Clarithromycin: Covariates Analysis



# Conclusion

- Extension of the SAEM algorithm to take into account a fused LASSO penalty on fixed, covariates and variances parameters
- Fused LASSO penalty is well suited to do group comparison
- Open question:  
Does this algorithm maximizes the penalized likelihood ?
- Perspectives:
  - Variance selection
  - Work in high dimensional settings
  - Take into account nested random effects (inter-occasion variability)